CoChat

Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human

Aerts, Joachim G.J.V., de Goeje, Pauline L., Cornelissen, Robin, Kaijen-Lambers, Margaretha E.H., Bezemer, Koen, van der Leest, Cor H., Mahaweni, Niken M., Kunert, André, Eskens, Ferry A.L.M., Waasdorp, Cynthia, Braakman, Eric, van der Holt, Bronno, Vulto, Arnold G., Hendriks, Rudi W., Hegmans, Joost P.J.J., Hoogsteden, Henk C. · 2018 · Clinical Cancer Research
Cited by 91

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Purpose: Mesothelioma has been regarded as a nonimmunogenic tumor, which is also shown by the low response rates to treatments targeting the PD-1/PD-L1 axis. Previously, we demonstrated that autologous tumor lysate–pulsed dendritic cell (DC) immunotherapy increased T-cell response toward malignant mesothelioma. However, the use of autologous tumor material hampers implementation in large clinical trials, which might be overcome by using allogeneic tumor cell lines as tumor antigen source. The purpose of this study was to investigate whether allogeneic lysate–pulsed DC immunotherapy is effective in mice and safe in humans. Experimental Design: First, in two murine mesothelioma models, mice were treated with autologous DCs pulsed with either autologous or allogeneic tumor lysate or injected with PBS (negative control). Survival and tumor-directed T-cell responses of these mice were monitored. Results were taken forward in a first-in-human clinical trial, in which 9 patients were treated with 10, 25, or 50 million DCs per vaccination. DC vaccination consisted of autologous monocyte–derived DCs pulsed with tumor lysate from five mesothelioma cell lines. Results: In mice, allogeneic lysate–pulsed DC immunotherapy induced tumor-specific T cells and led to an increased survival, to a similar extent as DC immunotherapy with autologous tumor lysate. In the first-in-human clinical trial, no dose-limiting toxicities were established and radiographic responses were observed. Median PFS was 8.8 months [95% confidence interval (CI), 4.1–20.3] and median OS not reached (median follow-up = 22.8 months). Conclusions: DC immunotherapy with allogeneic tumor lysate is effective in mice and safe and feasible in humans. Clin Cancer Res; 24(4); 766–76. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-2522

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 91

Metadata

Authors
Aerts, J. G. J. V., de Goeje, P. L., Cornelissen, R., Kaijen-Lambers, M. E. H., Bezemer, K., van der Leest, C. H., Mahaweni, N. M., Kunert, A., Eskens, F. A. L. M., Waasdorp, C., Braakman, E., van der Holt, B., Vulto, A. G., Hendriks, R. W., Hegmans, J. P. J. J., & Hoogsteden, H. C.
Venue
Clinical Cancer Research
Published
2018-02-14
Volume
24
Issue
4
Pages
766-776
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2772809021
Cited by
91
References
6
FWCI
3.14
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-2522
The paper
Aerts, J. G. J. V., de Goeje, P. L., Cornelissen, R., Kaijen-Lambers, M. E. H., Bezemer, K., van der Leest, C. H., Mahaweni, N. M., Kunert, A., Eskens, F. A. L. M., Waasdorp, C., Braakman, E., van der Holt, B., Vulto, A. G., Hendriks, R. W., Hegmans, J. P. J. J., & Hoogsteden, H. C. (2018). Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-2522

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.